Microparticle immune response modifier shows broad effects against recurrent or metastatic cancer

MIS416, a novel microparticle-based immune response modifier, demonstrated the ability to significantly reduce the number and size of metastatic tumors in preclinical mouse models of lung and breast cancers, Innate Therapeutics (formerly Virionyx Corporation) announced. Research presented today at the American Association of Cancer Research (AACR) meeting in Denver, CO by researchers from the Auckland, NZ company and their colleagues at the David Geffen School for Medicine, University of California, Los Angeles showed that MIS416 significantly inhibited tumor growth and the formation of metastases when tested as a stand-alone agent. When administered as an adjunct to localized tumor...

Want to see the full article?

• Purchase this article for only $3.00